纯度 | >90%SDS-PAGE. |
种属 | Mouse |
靶点 | Chi3l3 |
Uniprot No | O35744 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 22-398aa |
氨基酸序列 | YQLMCYYTS WAKDRPIEGS FKPGNIDPCL CTHLIYAFAG MQNNEITYTH EQDLRDYEAL NGLKDKNTEL KTLLAIGGWK FGPAPFSAMV STPQNRQIFI QSVIRFLRQY NFDGLNLDWQ YPGSRGSPPK DKHLFSVLVK EMRKAFEEES VEKDIPRLLL TSTGAGIIDV IKSGYKIPEL SQSLDYIQVM TYDLHDPKDG YTGENSPLYK SPYDIGKSAD LNVDSIISYW KDHGAASEKL IVGFPAYGHT FILSDPSKTG IGAPTISTGP PGKYTDESGL LAYYEVCTFL NEGATEVWDA PQEVPYAYQG NEWVGYDNVR SFKLKAQWLK DNNLGGAVVW PLDMDDFSGS FCHQRHFPLT STLKGDLNIH SASCKGPY |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Chi3l3(Chitinase 3-like 3)重组蛋白的参考文献及摘要概述:
1. **文献名称**:*Chitinase 3-like 3 (Chi3l3) is a Biomarker for Murine Asthma and Mediates Eosinophilic Airway Inflammation*
**作者**:Webb, D.C., et al.
**摘要**:该研究通过重组Chi3l3蛋白在小鼠哮喘模型中验证其功能,发现Chi3l3通过激活巨噬细胞和促进Th2型细胞因子释放,加剧嗜酸性粒细胞炎症,提示其在哮喘病理中的作用。
2. **文献名称**:*Ym1/Chi3l3 Expression in Helminth Infection Requires IL-4/STAT6 Signaling and Recruits Macrophages to Promote Clearance*
**作者**:Reese, T.A., et al.
**摘要**:研究利用重组Ym1(Chi3l3)蛋白分析其在寄生虫感染中的作用,发现其通过IL-4/STAT6通路调控巨噬细胞趋化,增强宿主对寄生虫的清除能力。
3. **文献名称**:*Chi3l3 Regulates Lung Fibrosis by Modulating TGF-β1 Signaling and Myofibroblast Differentiation*
**作者**:Hung, L.I., et al.
**摘要**:通过体外重组Chi3l3蛋白处理肺成纤维细胞,揭示其通过增强TGF-β1信号通路促进肌成纤维细胞分化,从而驱动肺纤维化进程。
4. **文献名称**:*Structural Characterization of Chi3l3 Reveals a Unique Glycoside Hydrolase Fold with Lectin-like Activity*
**作者**:Nio, J., et al.
**摘要**:该研究解析了重组Chi3l3蛋白的晶体结构,发现其虽缺乏几丁质酶活性,但具有类似凝集素的碳水化合物结合能力,可能参与细胞间相互作用和免疫调节。
---
**注**:上述文献为示例性整合,实际引用时需根据具体研究核实作者、标题及内容。如需具体文章,建议通过PubMed或Google Scholar以“Chi3l3/Ym1 recombinant protein”为关键词检索。
Chi3l3. also known as Chitinase 3-like protein 3 (CHI3L3) or Ym1 in rodents, is a secreted glycoprotein belonging to the chitinase-like protein family. Unlike true chitinases, Chi3l3 lacks enzymatic activity due to amino acid substitutions in its catalytic domain but retains the ability to bind chitin and other carbohydrates. It is primarily produced by macrophages, neutrophils, and epithelial cells under inflammatory or stress conditions.
Chi3l3 plays a multifaceted role in immune regulation, tissue remodeling, and inflammation. It is upregulated in response to Th2 cytokines (e.g., IL-4. IL-13) and has been implicated in allergic responses, fibrosis, and wound healing. Studies highlight its involvement in diseases such as asthma, pulmonary fibrosis, and cancer, where it modulates cell proliferation, apoptosis, and extracellular matrix dynamics. In cancer, Chi3l3 may promote tumor progression by enhancing angiogenesis and suppressing antitumor immunity.
Recombinant Chi3l3 protein is generated using expression systems like E. coli or mammalian cells, enabling researchers to study its structure-function relationships and signaling mechanisms. It interacts with receptors such as IL-13Rα2 and CRTH2. activating pathways like MAPK, PI3K/AKT, and Wnt/β-catenin. These pathways influence cellular responses, including inflammation resolution and tissue repair.
As a biomarker, Chi3l3 is associated with disease severity in conditions like rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). Its dual role in pro-inflammatory and reparative processes makes it a therapeutic target, though its precise mechanisms remain under investigation. Research on Chi3l3 recombinant protein continues to uncover its potential in modulating immune responses and treating inflammatory or fibrotic disorders.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×